Benitec Biopharma

175 articles about Benitec Biopharma

• Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

  4/18/2024

  Benitec Biopharma Inc. today announces positive interim clinical data from the 90-day timepoint following the administration of BB-301 to the study’s first subject (Subject 1) treated in the BB-301 Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study (NCT06185673) in Oculopharyngeal Muscular Dystrophy (OPMD).

• Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million

  4/18/2024

  Benitec Biopharma Inc.  today announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5,749,152 shares of its common stock at a price per share.

• Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024

  4/9/2024

  Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced it will host a virtual R&D Day, on Thursday, April 18, 2024 from 9:00 AM to 11:00 AM ET.

• Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update

  2/13/2024

  Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its second fiscal quarter ended December 31, 2023. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission.

• Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

  11/30/2023

  Benitec Biopharma Inc. today announced the first subject has been dosed in the BB-301 Phase 1b/2a Clinical Treatment Study.

• Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference

  11/17/2023

  Benitec Biopharma Inc. today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec, will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference on Thursday, November 30th, 2023 at 10:00 am ET.

• Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

  11/13/2023

  Benitec Biopharma Inc. announced financial results for its First Fiscal Quarter ended September 30, 2023.

• Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

  9/21/2023

  Benitec Biopharma Inc., a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference platform, announced financial results for its Fiscal Year ended June 30, 2023.

• Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering - August 11, 2023

  8/11/2023

  Benitec Biopharma Inc., a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference “Silence and Replace” platform, announced it closed its previously announced underwritten public offering of 15,544,041 shares of its common stock and accompanying warrants to purchase up to 15,544,041 shares of common stock.

• Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering

  8/9/2023

  Benitec Biopharma Inc. announced the pricing of its underwritten public offering of 15,544,041 shares of its common stock and accompanying warrants to purchase up to 15,544,041 shares of common stock.

• Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023

  7/25/2023

  Benitec Biopharma Inc., a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference

• Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

  6/26/2023

  Benitec Biopharma Inc. today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BB-301.

• Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

  5/15/2023

  Benitec Biopharma Inc., a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference platform, announced financial results for its Third Fiscal Quarter ended March 31, 2023.

• Benitec Biopharma to Present at the OPMD International Conference

  5/8/2023

  Benitec Biopharma Inc. announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will present virtually on the BB-301 Clinical Development Program at the Oculopharyngeal Muscular Dystrophy International Conference in Tel Aviv, Israel, on Tuesday, May 16th, 2023 at 12:50 pm Israel Daylight Time.

• Benitec Biopharma to Present at the JMP Securities Life Sciences Conference

  5/8/2023

  Benitec Biopharma Inc. today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec will present at the JMP Securities Life Sciences Conference on Tuesday, May 16th, 2023 at 2:00 pm.

• Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

  2/13/2023

  Benitec Biopharma Inc. announced financial results for its Second Fiscal Quarter ended December 31, 2022.

• Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

  1/23/2023

  Benitec Biopharma Inc. today announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program.

• Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

  11/10/2022

  Benitec Biopharma Inc., a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference platform, announced financial results for its Fiscal Year First Quarter ended September 30, 2022.

• Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

  9/16/2022

  Benitec Biopharma Inc. today announced it closed its previously announced underwritten public offering of 29,809,471 shares of its common stock.

• Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering - September 13, 2022

  9/13/2022

  Benitec Biopharma Inc. announced the pricing of its underwritten public offering of 29,809,471 shares of its common stock and accompanying warrants to purchase up to 29,809,471 shares of common stock.